Consort Medical PLC Director Declaration (5517W)
November 15 2017 - 4:14AM
UK Regulatory
TIDMCSRT
RNS Number : 5517W
Consort Medical PLC
15 November 2017
Registered Number 406711
Consort Medical plc
Director Declaration
In accordance with Rule 9.6.14 of the UK Listing Rules, Consort
Medical plc ('the Company') gives notice that Andrew Hosty, a
non-executive Director of the Company, has been appointed a
non-executive Director of RHI Magnesita N.V. with effect from 27
October 2017.
Enquiries:
Consort Medical plc
John Ilett, Company Secretary 01442 867920
Consort Medical plc is a leading, global, single source drug and
delivery device company (CDMO). We are at the leading edge of
innovation and we are committed to investing in patient, clinician
and customer driven innovation to create new treatments, new
markets and new opportunities.
Our businesses
Bespak is a global market leader in the manufacture of drug
delivery devices for pharmaceutical partner companies, including
respiratory, nasal, and injectable products, and the manufacture of
devices for the point of care diagnostics market.
www.bespak.com.
Aesica is a leading provider of finished dose and active
pharmaceutical ingredient (API) development and manufacturing
services to pharmaceutical partners. www.aesica-pharma.com.
We employ more than 2,000 people globally of which 1,400 are
located in the UK. We have UK facilities in King's Lynn, Cambridge,
Nelson, Milton Keynes, Cramlington, Queenborough and Hemel
Hempstead, German facilities in Monheim and Zwickau and a facility
in Pianezza, Italy. Consort Medical is a public company quoted on
the premium list of the London Stock Exchange (LSE: CSRT).
www.consortmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNEANFSFFDXFEF
(END) Dow Jones Newswires
November 15, 2017 04:14 ET (09:14 GMT)
Consort Medical (LSE:CSRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Consort Medical (LSE:CSRT)
Historical Stock Chart
From Apr 2023 to Apr 2024
